Neuphoria Therapeutics Inc.
NEUP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001191070
No open-market purchases or sales by Neuphoria Therapeutics Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $8.71M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Neuphoria Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Neuphoria Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Fisher Alan | Director | – | Jan 21, 2026 | 1 |
| Ryan Jane | Director | – | Jan 21, 2026 | 1 |
| Wilson David Ian | Director | – | Jan 21, 2026 | 1 |
| Davies Peter Miles Winston | Director | – | Jan 21, 2026 | 1 |
| Nichols Weston | 10% Owner | 875,328Indirect | Oct 23, 2025 | 1 |
| Lynx1 Capital Management LP | 10% Owner | 875,328Indirect | Oct 23, 2025 | 1 |
| Papapetropoulos Spyridon | President and CEO | – | Sep 2, 2025 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 2025 (view filing)7:49 PM ET | Oct 21 | 2 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.00001 par value per share | +639.1K | $5.14 | +$3.28M | +270.6%875.3K after |